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Background
The cytotoxic effects of ionizing radiation were first observed in 1895, when Wilhelm 
Röntgen intentionally subjected his finger to X-rays. Burns developed on the irradiated 
finger shortly after the exposure (Assmus 1995). Since then, ionizing radiation using 
both external and internal radiation sources has become one of the three pillars of anti-
cancer treatments along with surgery and chemotherapy (Zoller et al. 2009). Neverthe-
less, contemporary radiation techniques are frequently challenged by the need to deposit 
as much energy as possible in tumor regions while minimizing the collateral damage to 
normal tissues. Indeed, toxic side-effects are often the dose-limiting factors in many 
cases, and can prevent the further escalation of radiation dose (DeNardo and Denardo 
2006).
During the past several decades, nanomedicine has evolved into a promising player in 
cancer diagnosis and therapy (Retif et al. 2015; Li 2014). Nanoparticles can enhance the 
efficacy of radiotherapy through several mechanisms. The “targeted” nanoparticles, via 
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either passive or active mechanisms, can selectively deliver radioisotopes into tumors 
(Eetezadi et al. 2015). Radiosensitizers can also be delivered to solid tumors through the 
use of nano-carriers to make tumors more vulnerable to external radiation. In addition, 
nanoparticles are ideal platforms to incorporate multiple functions and enable multi-
modality therapy. For example, multiple chemotherapy drugs can be loaded in the same 
nanoparticles to achieve a synergistic anti-tumor effect with radiotherapy. Imaging capa-
bilities may also be integrated into nanoparticle design to provide image guidance (Phil-
lips et al. 2014).
External radiation sources
External beam radiation treatment (EBRT) utilizes an external linear accelerator to gen-
erate high-energy X-rays, and delivers them to tumors. The photon energy of X-rays 
ranges from kilo- to mega-volts. Compared to the kilovoltage X-rays, the megavoltage 
X-rays can irradiate deep-seated tumors with minimal burning of superficial tissues, and 
therefore are widely used in patients (Wang et  al. 2010). Along with the development 
of computer and electronic techniques within the past three decades, the way of deliv-
ering radiation beams has evolved significantly. The contemporary techniques include 
3D-conformal radiotherapy, intensity-modulated radiotherapy (IMRT), and image-
guided radiotherapy (DeNardo and Denardo 2006). Compared to conventional EBRT, 
IMRT delivers radiation dose with increased conformality, therefore limiting the dose 
exposure to normal organs (Samuelian et al. 2012). In a retrospective study by Samuelian 
et al. (Samuelian et al. 2012), 62% of patients experienced ≥grade-2 acute gastrointes-
tinal toxicity after conventional EBRT, while only 32% of patients had the same side-
effects following IMRT (p =  0.006). Stereotactic body radiotherapy (SBRT) is another 
novel technique that can deliver a large radiation dose to tumor while keeping a plum-
met of dose at the peripheral of target regions. In this way, the volume of irradiated nor-
mal tissues is minimized. SBRT has been successfully used in treating lung, liver, spine, 
kidney, and pancreatic cancers (Pollom et al. 2015).
Internal radiation sources
Free metal ions are rarely injected by themselves due to their unfavorable biodistribution 
profiles. For example, free 90Y ions tend to deposit in bone (~50% of injected radioac-
tivity) and cause bone toxicities (Ando et al. 1989). As a result, radioisotopes are often 
conjugated to carriers to achieve a tumor-specific accumulation. For instance, 90Y and 
177Lu are frequently conjugated to tumor-specific peptides in the peptide receptor radio-
nuclide therapy (PRRT) (van Essen et al. 2009). The anti-tumor efficacy of radioisotopes 
is affected by their tissue penetration: long-penetrating radioisotopes (e.g., 90Y) are more 
suitable for larger tumors, whereas short-ranged ones (e.g., 177Lu) can better treat micro-
metastases (Villard et al. 2012). In addition to β emitters, α emitters and Auger emitters 
also have been evaluated in cancer therapy due to their promising energy transfer prop-
erties. For example, 211Astatine is a synthetic α emitter with a mean linear energy trans-
fer value optimal for inducing DNA double-strand breaks (Langen et  al. 2015). Auger 
electrons (Kassis 2004), on the other hand, are low-energy electrons generated by the 
radioisotopes that decay by electron capture and/or internal conversion (e.g., 125Iodine, 
123Iodine, and 77Bromine). Such transitions of the inner-shell electrons result in a 
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characteristic atomic X-ray photon, or low-energy and short-range mono-energetic elec-
trons (collectively known as Auger electrons). Auger electrons have uniquely high values 
of linear energy transfer (~26 keV/µm) within several cubic-nanometers from the site of 
decay. They can generate far more damage to DNA strands than those high-energy elec-
trons. Several radioisotopes commonly used in radiotherapy are listed in Table 1.
Radioisotope‑loaded nanoparticles for internal radiation
Radiolabeling of nanoparticles via chelators
Bifunctional chelators are normally needed to introduce radioisotopes to nanoparticles 
to achieve high radiolabeling stability. Since many excellent reviews have been published 
in this area (DeNardo and Denardo 2006; Liu 2008; Anderson and Welch 1999; Pohlman 
et al. 2006), only a brief discussion is presented in this section.
The chemical structures of several chelators are listed in Fig. 1. Diethylenetriamine-
pentaacetic acid (DTPA) exhibits high efficiency of radiolabeling under mild condi-
tions, making it an attractive candidate to label nanoparticles sensitive to heat or pH. 
However, DTPA chelation is kinetically labile, and may cause the dissociation of radio-
isotopes in vivo (Camera et al. 1994). As an example, Werner et al. (2011) developed bio-
degradable PLGA–lecithin–PEG core–shell nanoparticles that encapsulated paclitaxel 
in the core and chelated 90Y on the surface via DTPA. Folic acid was conjugated to the 
surface of these nanoparticles as the targeting ligand. The resultant nanoparticles were 
75 ± 10 nm in size and −35 ± 5 mV in surface charge. In an orthotopic ovarian cancer 
xenograft model, mice receiving the nanoparticles with both paclitaxel and 90Y at a dose 
of 500 µg nanoparticles/mouse (20 µg paclitaxel and 1.85 MBq 90Y per mouse) showed 
significant survival advantage over those receiving monotherapies.
Table 1 Properties of commonly used radioisotopes in radiotherapy









161.5 β− Emax = 0.497 MeV
Emean = 0.149 MeV
2 mm (Giovacchini et al. 
2012; Nilsson et al. 
2011)γ 113 ~ 321 keV
188Rhenium
(188Re)
17 β− 2.12 MeV 3.5 mm (Lin et al. 2014; Phae-
ton et al. 2016)γ 155 keV
90Yttrium
(90Y)
64.1 β− Emax = 2.28 MeV
Emean = 0.935 MeV
4.1–11.3 mm (Giovacchini et al. 
2012; Kennedy 
2014)
Fig. 1 Examples of radioisotope chelators (Kennedy 2014): diethylenetriaminepentaacetic acid (DTPA), 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and N,N-bis(2-mercaptoethyl) –N’,N’-diethyl-
ethylenediamine (BMEDA)
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1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a macrocyclic 
chelator with kinetic inertness after chelation with radionuclides. However, the labeling 
yield can be affected by many parameters such as the DOTA concentration, pH, reac-
tion temperature, and heating time. Heating (e.g., >50 °C) is usually required for a high 
labeling efficiency. Under such conditions, the denaturing of bioactive antibodies or dis-
ruption of nanoparticles may be a concern (Li et al. 1994). Wilson et al. (2012) conju-
gated 177Lu3+ to the surface of tri-gadolinium nitride C80 endohedral metallofullerene 
nanoparticles (Gd3N@C80) via DOTA chelator. Previously, Gd3N@C80 nanoparticles 
have been examined as highly efficient contrast agents for magnetic resonance imaging 
(Fatouros et al. 2006). The radiolabeling yield for 177Lu3+ was 50% despite 12 h of reac-
tion at 40 °C. The anti-tumor activity of 177Lu3+-labeled Gd3N@C80 nanoparticles were 
evaluated in two orthotopic glioblastoma models (U87MG and GBM12) in mice after 
local–regional injection via convection-enhanced delivery (CED). During CED, a cath-
eter is directly placed into tumor via stereotactic methods, followed by a slow injection 
of anti-cancer agents under a positive pressure gradient. Compared to the simple intra-
tumoral injection, nanoparticles injected under the CED setting had a more uniform 
distribution inside the tumor. Doses of 0.25–1.35  MBq significantly increased animal 
survival in both glioma xenograft models. The positive response was attributed to the 
short penetration distance (0.7 mm) of 177Lu, which deposited the majority of radiation 
energy on tumor cells.
N,N-Bis(2-mercaptoethyl) –N’,N’-diethylethylenediamine (BMEDA) is frequently used 
to chelate 188Re (Bao et al. 2003; Chang et al. 2007), which shows potentials in cancer 
diagnosis and therapy because it emits both γ rays (155 keV) and β particles (2.12 MeV) 
(Deutsch et al. 1986). Huang et al. (2011) prepared 188Re-BMEDA-loaded liposomes with 
a radiolabeling efficiency of 88.0 ± 2.8%. The resulting liposomes were 80.3 ± 1.1 nm 
in average diameter and −1.44  mV in ζ potential. Seventy-four percent of 188Re was 
retained in liposomes after 72  h of incubation in serum. In an orthotopic rat glioma 
model, it was found that about 1.95% of injected dose was retained in each gram of 
tumor tissue (1.95% ID/g) at 24 h after intravenous injection. In comparison, the uptake 
in normal brain was less than 0.08% ID/g. Lin et al. (2014) prepared a similar liposomal 
formulation to treat non-small cell lung cancer (NSCLC) in an orthotopic tumor model. 
Compared to the small-molecule complex 188Re-BMEDA, 188Re-liposomes exhibited 
higher blood retention and higher tumor uptake. A single injection of 188Re-liposomes at 
a dose of 23.7 MBq/mouse effectively delayed tumor growth.
Other labeling techniques have also been used for introducing 188Re to nanoparti-
cles. Vanpouille-Box et al. (2011) prepared 188Re-labeled lipid nanocapsules using dith-
iobenzoate. In this technique, perrhenate 188ReO4− ion was first reduced by a cocktail of 
SnCl2/potassium oxalate/ascorbic acid/sodium gluconate, and then chelated by sodium 
dithiobenzoate to form a hydrophobic complex of 188Re(III)(PhCS3)2(PhCS2), abbre-
viated as 188Re-SSS (Lepareur et  al. 2004). 188Re-SSS was then physically loaded into 
lipid nanocapsules, which were locally injected into 9L rat glioma in immunocompe-
tent Fisher 344 rats by using CED technique at 2.8  MBq/injection for two injections. 
The nanocapsules significantly prolonged the tumor retention of 188Re-SSS: more than 
75% ID/g remained in brain at 96 h post injection. In contrast, 70% of injected 188ReO4− 
had been cleared from the body during the same time period. A promising cure rate of 
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83% was observed using an optimized treatment schedule. It is interested to note that 
188Re-SSS-loaded lipid nanocapsules also suppress the growth of secondary tumors, sug-
gesting a possible role of therapy-induced anti-tumor immune response.
The naturally existent porphyrins have exceptionally high affinity with metal ions and 
display intrinsic fluorescence (Smith and Gouterman 1968; Bases et al. 1958). Liu et al. 
(2013) labeled 64Cu to a porphyrin-based liposome (64Cu-porphysomes) to delineate 
prostate tumors in orthotopic models by using positron emission tomography (PET). At 
24 h after injection, the tumor uptake was 6.83 ± 1.08% ID/g in PC-3 and 4.81 ± 2.06% 
ID/g in 22RV1 prostate tumors in mice. Notably, micro-metastases as small as 1.4 mm 
were detected in bone. Since tumors at this size have limited angiogenic blood vessels, 
tumor uptake in small metastatic lesions may be facilitated by mechanisms other than 
the classical enhanced permeability and retention effect. Substitution of 64Cu with ther-
apeutic radioisotopes may render this class of nanoparticles suitable nano-carriers for 
treatment of micro-metastatic lesions.
Chelator-free radiolabeling of nanoparticles
Although it has been extensively used at both preclinical and clinical stages, chelator-
based radiolabeling still faces some limitations. There is no single chelator that binds to 
all isotopes with thermodynamic and kinetic stability. In many cases, the optimal chela-
tor for an isotope needs to be empirically determined. Moreover, the in  vivo stability 
of chelation can be compromised by endogenous protein trans-chelation, leading to the 
dissociation of isotopes from nanoparticles (Boswell et al. 2004).
We are among the first to introduce the concept of chelator-free radioactive nanopar-
ticles taking advantage of radioisotopes and their non-radioactive isotopes of the same 
element as integral components of nanoparticles. This is exemplified by the synthesis 
of chelator-free 64Cu-doped copper sulfide nanoparticles ([64Cu]-CuS NPs) (Zhou et al. 
2010). 64Cu is a unique radioisotope suitable for both PET imaging and radiotherapy, 
because it emits 0.653 MeV positron (17.8%) and 0.579 MeV beta particles (38.4%) at a 
half-life of 12.7 h. We have synthesized highly stable [64Cu]-CuS NPs with high radio-
chemical yield (Zhou et  al. 2010). These nanoparticles were 11.7  nm in size with cit-
rate coating, and 31.6 nm with polyethylene glycol (PEG) coating, and displayed strong 
absorption of near-infrared light. PET/CT imaging clearly delineated the U87 glioma 
xenograft at 24 h post injection, with a tumor uptake value of 7.6 ± 1.4% ID/g (Fig. 2). 
In subsequent studies, we demonstrated that PEG-[64Cu]-CuS could be used to treat 
anaplastic thyroid cancer (Zhou et al. 2015a). Intratumoral injection of PEG-[64Cu]-CuS 
at 7.4 MBq/mouse significantly delayed tumor growth compared to the non-treatment 
control (p < 0.0053), while no significant systemic toxicity was observed.
Black et al. (2014) added H198AuCl4 to the starting materials and directly incorporated 
198Au into the crystal lattice of Au nanostructures. The specific activity was tuned by 
changing the ration of H198AuCl4 to HAuCl4. The γ emission from 198Au enabled single-
photon emission computed tomography (SPECT), while the β emission produced lumi-
nescence imaging via Cerenkov radiation.
Later work extended the concept of chelator-free radiolabeling to nanoparticles with 
radioisotopes that are not part of the building components of the nanoparticle. For exam-
ple, Shaffer et al. (2015) reported silica nanoparticles for a generalized immobilization of 
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radionuclides, including 89Zr, 68Ga, 111In, 90Y, 177Lu, and 64Cu. The radionuclides were 
bound by the oxygen atoms of the silica lattice. Radiolabeling was performed in a range 
of pH values (pH = 5.7–8.8) at 70 °C for 15 min, to give an efficiency >99% and a spec-
ificity of 3.7 TBq/µmol. Radovic et  al. (2015) absorbed 90Y3+ ions onto the negatively 
charged surface of Fe3O4 nanoparticles, with a labeling yield >99%. However, 5–20% of 
the 90Y dissociated after 1 week. Liu et al. (2015) absorbed 64Cu on the surface of MoS2 
nanosheets through the high affinity between Cu and S ions; 70–85% labeling efficiency 
was achieved by shaking at 37 °C for 1 h. The labeling was stable (>85% retention) dur-
ing serum incubation at 37 °C for up to 48 h. Chelator-free labeling of nanoparticles by 
surface absorption is in general less stable compared to labeling with radioisotopes to be 
integrated to the matrix of the nanoparticles.
Sun et al. (2014) prepared 64Cu-doped CdSe/ZnS core/shell quantum dots via cation 
exchange reaction in organic phase. After 1 h of incubation at 60  °C, the labeling effi-
ciency was almost 100% with a specific activity of 7.4 MBq/mg of quantum dots. The 
shape and size of quantum dots were preserved after radiolabeling. The labeling was 
highly stable during serum incubation at 37  °C for up to 48  h. Notably, the encapsu-
lated 64Cu enabled the Cerenkov luminescence and irradiated the quantum dots to gen-
erate luminescence. A similar method was used by Guo et al. (2015) for the preparation 
of 64Cu-labeled CuInS/ZnS quantum dots. In another study, Sun et al. (2014) prepared 
64Cu-coated Au nanoparticles by reducing 64Cu2+ with hydrazine in the presence of Au 
nanoparticles. The formed 64Cu element deposited on Au surface to achieve a radiolabe-
ling up to 100% efficiency. Various Au nanoparticles were successfully labeled without 
changes in morphology or size.
Chloramine T oxidation is a common method for radioiodination of antibodies (Yam-
ada et  al. 2000). During the reaction, iodide is first oxidized to iodine monochloride, 
which then reacts with aromatic rings to form an iodine-tagged aromatic ring. Chlora-
mine T oxidation has been used to label PEG-coated graphene nanosheets (PEG-GNS). 
Yang et al. (2011) prepared 125I-PEG-GNS with a labeling efficiency between 50 and 60% 
and a specific activity of 7.4 MBq/mg of NGS. Less than 5% of 125I detached after 15 days 
of incubation at 37 °C in saline or serum. Chen et al. (2015) used 131I-labeled PEG-GNS 
for the radiation/photothermal therapy in a 4T1 murine breast cancer model. The result-
ant 131I-PEG-GNS was 50 nm in size and 3 nm in height. A majority of nanoparticles 
Fig. 2 [64Cu]–CuS nanoparticles were used for both PET imaging (a) and radiotherapy (b). [reused with 
permission from references (Zhou et al. 2010, 2015a)]
Page 7 of 23Zhao et al. Cancer Nano  (2016) 7:9 
were entrapped in liver and spleen (15–20 ID %g ) with a tumor uptake value of 5% ID/g 
at 48 h after intravenous injection at a dose of 100 mg/kg (7.4 MBq/mouse). Radiother-
apy reduced tumor volume by about 70% at 18 days after treatment, while the combina-
tion therapy eliminated tumor in 4 out of 5 mice. No significant toxicities were observed 
in terms of liver, spleen, hematological toxicities, or body weight loss.
Neutron-activated nanoparticles
166Ho is an attractive radionuclide for radiotherapy by emitting both gamma photons 
(81 keV, 6.6%) and high-energy β particles (maximum energy at 1.84 MeV) at a half-life 
of 26.8 h. It also provides contrast to CT and MRI due to its high attenuation coefficient 
and paramagnetic properties, respectively (Seevinck et al. 2007). 166Ho-labeled nanopar-
ticles can be prepared through the neutron activation of the stable isotope 165Ho. The 
yield of 166Ho conversion is proportional to the duration of neutron activation. Di Pas-
qua et al. (Di Pasqua et al. 2013) doped MCM-41-type mesoporous silica nanoparticles 
(MSN) with 165Ho(AcAc)3, which was then converted to 166Ho by neutron activation. 
The resultant 166Ho-MSN nanoparticles were 80–100 nm in size and −49.2 ± 6.0 mV 
in surface charge, with a specific activity of 12 MBq/mg. 166Ho-MSN was evaluated in 
an orthotopic SKOV3 ovarian cancer xenograft model by intraperitoneal injection. The 
tumor uptake (ID%/g) was 32.8 ± 8.1% at 24 h post injection, and reached 81 ± 7.5% 
1 week after. It should be noted that the tumor uptake value reported here was remark-
ably high compared to many other radioisotope-labeled nanoparticles. However, no 
explanation was given for the underlying tumor-homing mechanism, which may be in 
part attributed to the intraperitoneal injection route. In terms of anti-tumor efficacy, one 
injection of 4 MBq 166Ho-MSN reduced the tumor metabolism activity by 50% compared 
to control. Ninety-seven percent of the treated mice were alive at 75  days post-treat-
ment, which was significantly higher than the groups without treatment or receiving free 
166Ho alone. In a follow-up study, Munaweera et al. (2015) prepared 165Ho-doped gar-
net magnetic nanoparticles and loaded them with platinum-based radiosensitizers. The 
formed nanoparticles were 40.7 ± 16.4 nm in length and 26.9 ± 8.0 nm in width, with 
typical ferromagnetic behaviors. Up to 6.2% (by weight) of platinum was loaded, and the 
specific activity was 9.25 MBq/mg.
Biological considerations for radiotherapy
Administration routes of nanoparticles
In preclinical studies, nanoparticles are commonly administered via intravenous or 
intratumoral injection. Compared to intravenous injection, intratumoral injection of 
nanoparticles can directly deposit large doses to tumor site, without the toxicity to other 
organs. The theoretical simulations by Sinha et  al. (2015) suggested that intratumoral 
injection of AuNPs provided better radiosensitization effects than intravenous injec-
tion. However, intratumoral injection is considered as a local therapy and is not suitable 
for treating disseminated disease. Due to the presence of brain–blood barrier in brain 
tumors, convection-enhanced delivery (CED) can provide a more uniform intratumoral 
distribution of nanoparticles (Fatouros et al. 2006). For pulmonary malignancies, on the 
other hand, inhalation is a viable option (Muralidharan et al. 2015). For ovarian cancer, 
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intraperitoneal injection is sometimes used to increase exposure of tumors to the radio-
active nanoparticles in the abdomen cavity (Di Pasqua et al. 2013).
In addition to tissue distribution, the radiosensitization effects of nanoparticles 
depend on their concentration as well as distribution inside cells. McQuaid et al. (2016) 
studied the correlation between intracellular distribution of gold nanoparticles and the 
range of DNA-damaging electrons produced during radiation. Chithrani et  al. (2010) 
showed that AuNPs of 50 nm in size were optimal for cellular uptake and therefore more 
potent than both larger and smaller AuNPs in terms of radiosensitization. It is known 
that AuNPs, under radiation, can generate secondary electrons and damage DNAs 
within 30 nm range (Zheng et al. 2008). Therefore, intranuclear AuNPs can better induce 
DNA damage than the cytoplasmic ones. Oh et al. (2011) examined the intracellular dis-
tribution of gold nanoparticles (AuNPs). Small AuNPs (~2.4 nm) localized in nucleus, 
while larger ones (5.5–8.2 nm) retained in the cytoplasm in a perinuclear manner. Zhang 
et al. (2012) compared the radiosensitization effect of PEG-coated AuNPs with sizes of 
4.8, 12.1, 27.3 and 46.6  nm. Transmission electron microscopy (TEM) studies found 
that 4.8- and 46.6-nm AuNPs formed large aggregates when taken by HeLa cells, while 
the 12.1- and 27.3-nm AuNPs had more uniform distribution. The in vivo biodistribu-
tion study revealed that the 12.1-nm AuNPs had the highest tumor uptake. Since the 
radiosensitization effect is favored by a high intratumoral concentration of AuNPs, the 
best radiosensitization effect was achieved by the 12.7-nm AuNPs. Rima et  al. (2013) 
examined the intracellular delivery of sub-5 nm gadolinium-based nanoparticles in head 
and neck squamous cell carcinoma cells. TEM images established that the nanoparti-
cles were internalized via passive diffusion and micropinocytosis, while the latter led to 
a successful radiosensitization in cell culture. In a follow-up study, Stefancikova et  al. 
(2014) revealed that the gadolinium-based nanoparticles co-localized with lysosomes in 
U87 cells and still provide radio-enhancement under gamma irradiation.
In vivo dosimetry of nanoparticle-bound radionuclides
The radiation energy absorbed by tumor or normal tissues is an important predictor to 
the biological responses in each tissue (Zoller et al. 2009). The absorbed dose, a quantifi-
cation of such energy, is defined as the energy absorbed per unit mass of tissue (Sgouros 
2005). In addition, the tissue responses are also affected by the rate of dose delivery, the 
type of radiation sources (e.g., α, β, or Auger particles), the radiobiological characteristic 
of each tissue, as well as the treatment history of patients (Sgouros 2005). Since most 
nanoparticle-bound radionuclides are used inside the body, a brief introduction to the 
dosimetry of internal emitters will be discussed in this section.
Absorbed dose (D) is the appropriate term of dosimetry in practice, defined as the 
energy (E) absorbed by the tissue, divided by the tissue mass (M):
where E =  number of radionuclide disintegrations in a defined volume (Ă) ×  energy 
emitted per disintegration (Δ)  ×  fraction of energy absorbed by the tissue mass (ϕ). 
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temporal distribution. In clinics, the radioactivity from the region of interest is recorded 
by imaging or sampling, and plotted into a curve against time. The integral of this activ-
ity–time curve give the value for Ă. The second term, Δ, is related to the emission type, 
and can be derived from standard dosimetry tables (Browne et al. 1986). The last term, ϕ, 
accounts for the fraction of energy absorbed in the target region that is emitted from the 
source tissue, and commonly denoted as ϕtarget←source. ϕ is generally derived from Monte 
Carlo calculations (Snyder et al. 1969). In practice, Δ, ϕ and M are combined into one 
parameter S, and the total absorbed dose (DT) is the sum of doses contributed by differ-
ent sources:
The list of S values can be found from pamphlets published by the Committee on 
Medical Internal Radiation. However, it should be noted that due to the irregular geom-
etry of tumor, the S values generated from the idealized tables may provide erratic infor-
mation of absorbed doses. Advanced imaging techniques and mathematical simulations 
have been developed for more accurate estimation (Sgouros 2005).
Radiation-induced toxicity in healthy organs
Few studies report nanoparticle-mediated radiotoxicity to normal organs. Since nano-
particles are largely distributed to organs of the mononuclear phagocytic system or kid-
ney, we will briefly discuss the general radiotoxicity of liver and kidney.
Liver
In general, the whole liver can be safely irradiated with up to 30–35 Gy (Lawrence et al. 
1995). Higher doses may cause subacute toxicity at 4–8  weeks post radiation, com-
monly known as the veno-occlusive disease (Fajardo and Colby 1980). It is characterized 
by congestions in the central portion of liver lobes due to the entrapped erythrocytes, 
as well as the obstructed sub-lobular veins by collagen fibers. Collagen proliferation 
may also obstruct some small portal veins toward the end period of subacute damage. 
Although liver could heal over time after radiation, the asymptomatic chronic injuries 
may still persist up to 6 years post radiation, such as the distorted structures and fibrosis 
of liver lobules and veins. Such chronic lesions may be associated with chronic radiation 
hepatitis in clinics (Lewin and Millis 1973).
Kidney
Radiation-induced kidney damage can be characterized into acute and chronic nephrop-
athy. The acute symptoms, such as proteinuria, hypertension, heart failure, azotemia, 
and anemia, reflect the pathological changes in kidney including atrophy, tubulointer-
stitial scarring, mesangiolysis, and thrombotic microangiopathy. The chronic symptoms, 
on the other hand, are characterized by the loss of mass and functions in kidney (Moll 
et al. 2001; Behr et al. 1999). In a follow-up survey, Valkema et al. (2005) observed a sus-
tained decline of creatinine clearance in patients for up to 5.4 years after receiving PRRT.
Kidney can be safely treated with 15–17  Gy of EBRT in 2-Gy fractions. In case of 
nanoparticle-bound radionuclides, however, the threshold dose may be significantly dif-
ferent; because, both clearance and re-absorption of radionuclides can occur in kidney. 
DT =
⌣
AS1 × ST←S1 +
⌣
AS2 × ST←S2 +
⌣
AS3 × ST←S3 . . .
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Although currently few studies discuss the renal toxicity caused by radiolabeled nano-
particles, the PRRT-induced kidney damages have been reported (Giovacchini et  al. 
2012; Vegt et al. 2010). For instance, Svensson et al. (2012) showed that proximal tubu-
lars of nude mice can be damaged by 177Lu-DOTA-Tyr3-octreotate above 24 Gy.
Figure 3 shows the trafficking of peptides and small molecules in kidney. It is known 
that molecules less than 1.8 nm are rapidly filtered through the glomerular membranes 
and enter the proximal tubules, while those larger than 4–6 nm are mostly retained in 
blood circulation (Vegt et  al. 2010). The filtrate inside proximal tubules, however, can 
be re-absorbed into blood circulation via active or passive transport. Oligopeptides can 
be hydrolyzed at the brush border of proximal tubular cells, and re-absorbed by trans-
porters. Large peptides or proteins, on the other hand, are mainly absorbed by receptor-
mediated endocytosis (Christensen and Verroust 2002; de Jong et al. 2005). It should be 
noted that some radiolabeled metabolites cannot escape the lysosomes of tubular cells, 
and thus reside in kidney and potentially cause radiation toxicity.
Renal toxicities can be alleviated by reducing the absorbed doses. Uehara et al. (2007) 
incorporated a cleavable glycyl–lysine linker between 188Re and antibody fragments, 
which was cleaved at the brush border of proximal tubules. As a result, 188Re was not 
absorbed along with the antibody. The re-absorption of proteins can be lowered by co-
injecting other molecules, including lysine, arginine, poly-l-lysine, succinylated gelatin, 
Fig. 3 Clearance and re-absorption of peptides and small molecules in kidney. Used with permission from 
Ref. (Behr et al. 1999). This research was originally published in [71], by the Society of Nuclear Medicine and 
Molecular Imaging, Inc
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fractionated albumin, and albumin-derived peptide (Pimm and Gribben 1994). Another 
method is to inhibit the receptor-mediated endocytosis. For example, the renal uptake of 
111In-octreotide was reduced by probenecid, which inhibits ochratoxin A transport and 
multidrug resistance proteins (Stahl et al. 2007).
Nanoparticles for radiosensitization
Despite the improvement in imaging and radiation sources, it is still a great challenge 
to confine the curative dose of radiation within tumor tissue while sparing the adjacent 
normal tissues. In many cases, the radio-toxicities to non-tumor tissues remain the 
dose-limiting factors. Therefore, it is of great benefit to increase the sensitivity of tumor 
cells to radiation, so that lower radiation doses can be used to eradicate tumor. Up to 
date, a plethora of radiosensitizers have been developed and evaluated based on different 
mechanisms, such as enhancement of dose, generation of radical oxygen species (ROS), 
and alteration of biological responses to radiation. A brief discussion of nanoparticles 
equipped with radiosensitization capabilities are presented as follows.
Dose enhancement using high atomic number (Z) materials
Dose enhancement during radiotherapy was pioneered by Matsudaira et  al. (1980), 
where iodine (Z =  53) was found to increase the absorbed dose of X-rays in cell cul-
ture. Since then, the dose enhancement has been extended to various metal elements, 
including gold (Au, Z = 79) (Schuemann et al. 2016), gadolinium (Gd, Z = 64), plati-
num (Pt, Z = 78), and bismuth (Bi, Z = 83) (Chithrani et al. 2010; Kamiar et al. 2013; 
Jeremic et al. 2013; Alqathami et al. 2013; Yao et al. 2014; Ma et al. 2015; Le Duc et al. 
2011; Miladi et al. 2013; Kryza et al. 2011; Miladi et al. 2015; Porcel et al. 2010; Usami 
et al. 2007, 2008). Notably, Gd-based nanoparticles presented both diagnostic and thera-
peutic potentials, since Gd also provides MRI contrast (Le Duc et  al. 2011). Classical 
models have attributed the radiosensitization to the physical dose enhancement arising 
from the keV electrons. However, biological and chemical changes may also occur that 
subsequently increase the sensitivity of cells or tissues to radiation. The actual biological 
effects may come from both perspectives (Subiel et al. 2016).
Extensive studies have focused on exploring the underlying mechanisms of radiosen-
sitization via high-Z metals (Porcel et al. 2010). An excellent overview was presented by 
Hainfeld et al. in their report of AuNP-enabled radiosensitization (Hainfeld et al. 2008). 
In general, high-Z atoms have large cross sections to absorb radiation energy, after 
which secondary radiations can be generated to cause damages in nearby DNA mole-
cules. Such secondary radiations include short-range low-energy electrons, Auger elec-
trons, photoelectrons, and characteristic X-rays (Jeremic et al. 2013). The ranges of such 
secondary electrons in tissue vary from about 10 nm for the Auger electrons, to 100 µm 
for the photoelectrons, and as far as several centimeters for the fluorescence photons 
(Hainfeld et al. 2008). Using gold as an example, the dose enhancement is restricted to 
the vicinity of gold atoms. It is critical to have a uniform distribution of gold throughout 
the whole tumor, or more preferentially close to DNA molecules. As a result, nanopar-
ticle formulations are advantageous due to their ability to selectively deposit in tumor 
and to be internalized by tumor cells (Oh et al. 2011). Indeed, micrometric gold nano-
particles were restricted to the site of injection, instead of distributing throughout the 
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tumor (Herold et al. 2000). It should be noted, however, majority of the nanoparticles 
reside within cytoplasm unless a specific nuclei-delivery is incorporated in the design 
of nanoparticles. It remains of question whether DNA damage can be induced by the 
secondary electrons produced from cytoplasmic nanoparticles. On the other hand, the 
dose enhancement factor (DEF) by AuNPs varies with radiation sources. A simulation 
study by Lin et al. (2015) calculated that 43% additional dose was produced by AuNPs 
for 250 keV photons, 1% for 6 MeV photons, and only 0.1% for protons. Rahman et al. 
(2014) irradiated 1.9-nm AuNPs with X-rays from 30 to 100 keV. The 40-keV X-ray had 
the highest DEF at 3.47, while both lower and higher energy X-rays had lower DEFs. A 
probable explanation is that low-energy photons can be absorbed by the K or L shell 
electrons of Au. The resultant secondary Auger electrons emission then causes further 
damage to DNAs. In contrast, high-energy photons tend to have Campton scattering 
without producing Auger electrons (Kobayashi et al. 2010).
Hainfeld et al. (2004, 2006, 2008) first examined the in vivo radiosensitization effect 
of 1.9-nm AuNP in a murine EMT-6 mammary tumor model. Mice were injected with 
a dose of 1.35 gAu/kg, which resulted in a 4.9 ± 0.6% ID/g tumor uptake at 5 min post 
injection. For radiation therapy, 30 Gy of 250 kV X-ray was applied to the tumor region 
at 2 min post injection of AuNP. Most tumors were undetectable at 1 month after treat-
ment with AuNP plus radiation, while the monotherapy groups only delayed tumor 
growth. Long-term survival studies (up to 1 year) also showed a benefit of the combina-
tion therapy as well as a response dependent on the dose of gold (Hainfeld et al. 2004). 
While many studies have proven the radiosensitization effects of AuNPs in both cell 
culture and animal models, the long-term body retention of AuNPs remains a concern 
despite that AuNPs are often considered safe and bio-inert (Zelasko-Leon et al. 2015). 
To minimize such potential chronic toxicity, several clearable formulations of AuNPs 
were developed. Zhang et al. (2015) prepared 2.8-nm glutathione-protected AuNPs for 
radiosensitization. The combination therapy of AuNPs and 5 Gy of 137Cs radiation com-
pletely inhibited the growth of U14 brain tumor xenograft. Notably, the ultrasmall 2.8-
nm AuNPs had minimal uptake in the RES organs such as liver and spleen, and were 
cleared via kidney. The body clearance of AuNPs was completed at 28 days after injec-
tion. The same group also studied the sub 2-nm glutathione-protected AuNPs (Zhang 
et al. 2014), showing similar radiosensitization effects. In this study, however, significant 
liver uptake (~30% ID/g) was found at 24 h post injection. Such discrepancy may arise 
from the fact that fluorescence dye Cy5 was conjugated to AuNPs and used as tracer for 
uptake studies. The dissociation and subsequent retention of Cy5 in liver may cause a 
falsely high uptake of AuNPs. Further studies are required to clarify such an issue.
Other metal elements were also tested for dose enhancement. Gadolinium-based (Gd, 
Z = 64) ultrasmall nanoparticles (GBNs) have been evaluated for radiosensitization by 
a group of French researchers (Le Duc et al. 2011; Miladi et al. 2013; Kryza et al. 2011; 
Miladi et al. 2015). The GBNs are composed of a Gd2O3 core surrounded by a silica shell, 
with a hydrodynamic diameter of 3.8 ± 0.1 nm. Biodistribution study found a high rate 
of renal clearance after the intravenous injection of GBNs. Over 95% of injected dose 
was eliminated within 18 days after injection, via both urine and feces. The small size 
also reduced the fenestration in organs of the mononuclear phagocytic system, showing 
a minimal uptake in liver (<0.5% ID/g) (Kryza et al. 2011). Le Duc et al. (2011) evaluated 
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the GBNs in a rat model bearing intracerebral 9L gliosarcoma along with microbeam 
radiotherapy. DTPA was coated to the surface of GBNs to chelate Gd3+ ions and subse-
quently provide MRI contrast. MRI delineated the tumor up to 45 min after intravenous 
injection of GBNs, with a tumor-to-tissue ratio of 60.4 being reached at 20  min post 
injection. Microbeam radiotherapy was applied to tumor at 20 min post injection, and 
the mean survival time was extended to 90 days, compared to 47 days for radiation-only 
control, and 19 days for non-treatment control. Miladi et al. (2015) examined the GBNs 
in several radio-resistant human head and neck squamous cell carcinoma models along 
with 250 keV photon irradiation. The combination of GBNs and radiation overcame the 
radiation resistance in SQ20B stem-like cells, significantly delayed tumor growth with 
elevated late apoptosis and reduced cell proliferation. Sancey et al. (2014) reviewed in 
detail the evolution of Gd-based theranostic nanoparticles, which has recently been 
benchmarked as AGuIX®. It should be noted that high radiosensitization effects were 
reached even with a Gd concentration as low as 1 ppm in tumor. Auger electrons were 
believed to be the main contributor for radiosensitization under such scenarios.
The radiosensitization of platinum-based nanoparticles has been explored (Porcel et al. 
2010; Usami et al. 2005, 2007, 2008, 2010), especially in combination with fast atomic 
ions such as Fe26+ and C6+. Unlike photons and electrons, such heavy atoms with large 
cross sections interact with tissues on their trajectory tracks, and therefore are more 
efficient than conventional radiations (Dan et  al. 2003; Mozumder 2003). Porcel et  al. 
(2010) showed that both Pt ions and 3-nm Pt nanoparticles bound to DNA molecules, 
and increased the number of single-strand breaks and double-strand breaks during 
radiation. The enhancement ratios were between 1.37 and 2.17. Importantly, DNA dam-
ages were significantly alleviated by adding radical scavengers, indicating that radiation-
induced water radicals were a prominent culprit of DNA damage (Usami et  al. 2007). 
Since DNA is generally accepted as the main target of ionizing radiation in cells, the 
produced DNA damages may serve as a probe to quantify the radiation-enhancing effect 
of nanoparticles. Gel electrophoresis has been used to quantify the number of single- 
and double-strand breaks ex vitro (Usami et al. 2007), while many staining techniques 
are available to visualize the DNA breaks in cell culture or tissues (Mah et al. 2010; Zhu 
et al. 2014).
Bismuth (Bi, Z = 83)-based nanoparticles have shown to induce above 80% enhance-
ment of radiation dose while maintaining low toxicities (Alqathami et al. 2013). Yao et al. 
(2014) prepared Bi2S3-loaded PLGA nanoparticles. The resultant nanoparticles were 
754.6 nm in size and distributed to PC3 prostate xenograft tumor within 30 min of injec-
tion, although 80% of injected dose was fenestrated in liver. The combination therapy 
with 6-Gy radiation and Bi2S3-PLGA inhibited tumor growth more effectively than 
monotherapy groups, along with the upregulation of apoptosis-related proteins, includ-
ing p53, Bax, and Bcl-2. Ma et  al. (2015) prepared Bi2S3-embedded mesoporous silica 
nanoparticles (BMSNs) for radiosensitization. Hydrophobic Bi2S3 nanoseeds of 2–3 nm 
in diameter were first prepared, followed by a sol–gel condensation of triethoxysilane, 
to form the mesoporous nanoparticles of 72.7 nm in size. BMSNs were used in combi-
nation with 1.85 MBq interstitial 32P irradiation to treat PC3 prostate xenograft tumor. 
Compared to monotherapies, the combination therapy effectively inhibited tumor 
growth and induced prominent apoptosis of tumor cells.
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Generation of reactive oxygen species (ROS)
Radiation-generated ROS is an important cytotoxic component for killing cancer cells 
(Allison et al. 2004). The cytotoxic ROS can also be generated via photodynamic therapy 
(PDT). PDT is an emerging non-invasive treatment that utilizes light-excitable photo-
sensitizers to produce cytotoxic ROS upon photon illumination (O’Connor et al. 2009). 
Unlike many other chemotherapy drugs that need to enter cytoplasm or nucleus to func-
tion, the major target of ROS are lysosomes that belong in the endocytosis pathway of 
nanoparticles (Leamon and Low 1991). Therefore, endosome escape is not required for 
the ROS-generating nanoparticles to exert cell-killing effects. Once lysosomes are rup-
tured by ROS, cathepsin B or L are released to activate caspases, which in turn inac-
tivates proteins that protect cells from apoptosis (de Castro et al. 2016). Conventional 
PDT has two drawbacks. First, the generation of ROS requires oxygen, and therefore has 
limited efficiency in the hypoxic tumor microenvironment (Vaupel et al. 2001). Second, 
traditional photosensitizers are excited by ultraviolet or visible lights that have limited 
tissue penetration (Allison et al. 2004).
Recently, semiconductor nanoparticles have been developed that can downconvert the 
X-ray energy into ultraviolet/visible region, which can subsequently activate the nearby 
photosensitizers (Bulin et  al. 2013). Zhang et  al. (2015) prepared 33-nm cerium(III)-
doped LiYF4@SiO2@ZnO nanoparticles that can generate cytotoxic hydroxyl free radi-
cals upon X-ray irradiation. The X-ray was downconverted to ultraviolet fluorescence 
in the cerium(III)-doped LiYF4 core, and further generated electron–hole (e−–h+) pairs 
in ZnO. Highly reactive hydroxyl radicals were produced from the reaction between 
the hole (h+) and surrounding water. Since no oxygen was involved in the reaction, free 
radicals were generated in both normoxic and hypoxic conditions. Importantly, the 
inorganic photosensitizer was resistant to photobleaching during X-ray treatment. The 
combination therapy of the nanoparticle with 8-Gy X-ray radiation effectively inhibited 
the growth of HeLa xenograft tumor up to 15 days after treatment.
Auger effects may increase ROS generation upon X-ray irradiation (Kobayashi et  al. 
2010). He et  al. (2015) prepared mesoporous silica nanoparticles loaded with seleno-
cysteine (SeC@MSNs). The ROS generated by SeC@MSNs and 2-Gy X-ray via Auger 
effects was 202% of control. Extensive cell apoptosis was recorded, evidenced by the sub-
G1 population in cell cycle analysis. The activation of apoptosis pathways, e.g., p53 and 
ATM/ATR, was also observed. In  vivo anti-tumor efficacy in HeLa xenograft showed 
that combination group had the smallest tumor volume. In a similar study, Huang et al. 
(2014) conjugated bovine serum albumin with phenylbenzo (Assmus 1995; Zoller et al. 
2009; Li 2014) selenadiazole derivatives. The resultant nanoparticles also generated 
ROS upon X-ray irradiation, and radiosensitized HeLa xenograft tumor. Alternatively, 
nanoparticles can catalyze the production of hydroxyl radicals in aqueous solution upon 
X-ray irradiation (Sicard-Roselli et al. 2014).
It is known that the efficacy of radiotherapy can be mitigated by the hypoxic tumor 
microenvironment (Vaupel et  al. 1991). Prasad et  al. (2014) prepared MnO2-bound 
albumin nanoparticles (A–MnO2) to re-oxygenate the tumor microenvironment. The 
hypoxic tumor microenvironment and the highly proliferating tumor cells, together, pro-
duce ROS, e.g., H2O2. MnO2 reacts with the H2O2 to produce O2. Within 7 min of intra-
tumoral injection of A–MnO2, the vascular saturated O2 increased by 45% compared 
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to control. Immunohistochemical staining found decreased expression of both hypoxia 
markers HIF-1α and VEGF in treated tumor. When combined with radiation, a signifi-
cant inhibition of tumor growth was observed, along with elevated staining of DNA 
double-strand breaks.
Re-distribution of cell cycles to radiosensitive G2/M phases
While most radiosensitization experiments are conducted using keV-energy radia-
tion sources, current clinical therapy has shifted toward higher energy (MeV) sources 
in order to treat deep-seated tumor, as well as to reduce toxicity to skin (Jeremic et al. 
2013). However, the DEF of AuNPs is only marginal, between 1.1 and 1.2, for MeV 
X-rays. Nevertheless, a series of studies were performed on the combination of 6 MeV 
radiation and AuNPs of sizes between 13 and 55  nm (Liu et  al. 2015; Li et  al. 2015; 
Wang et  al.2015). Although radiosensitization effects were still observed, the underly-
ing mechanism was found not due to dose enhancement, but rather the re-distribution 
of cell cycles to the radiosensitive G2/M phases by AuNPs. Cyclin A, cyclin B1, cyclin 
E, and p53 are the critical mediators of AuNP-induced arrest of cell cycles (Roa et al. 
2009). Liu et  al. (2015) used EGFR-targeting hollow gold nanospheres to enhance the 
MeV radiation in cervical cancer. Uptake of hollow gold nanospheres induced cell arrest 
in G2/M phase (38.4 vs.10.2% in control), leading to increased cell apoptosis during 
radiation. In addition, the hollow gold nanospheres elevated the expression of pro-apop-
totic regulator, which may also have contributed to the radiosensitization. Wang et al. 
(2015) combined thioglucose-modified AuNPs (16 or 49 nm) with 6 MeV X-ray irradia-
tion for the treatment of MB-MDA-231 triple-negative breast cancer cells. Cell arrest in 
G2/M phases was observed in cells treated with AuNPs of both sizes. However, it is not 
clear how AuNPs caused cell arrest in G2/M phase, which remains to be studied. The 
49-nm AuNPs had higher uptake in cancer cells, and subsequently had higher sensitive 
enhancement ratio (SER) at 1.86 than the 16-nm ones (SER = 1.49).
Chemotherapy drugs constitute another category of cell cycle regulators (Russo et al. 
2016; Li et al. 2016), among which paclitaxel is widely used to treat various types of can-
cer (Pazdur et al. 1993). Paclitaxel promotes the assembly of microtubules and inhibits 
their disassembly (Pazdur et  al. 1993). Cells treated with paclitaxel are predominantly 
arrested in G2/M phases, and therefore have increased sensitivity to radiation (Creane 
et al. 1999). Due to its limited water solubility, paclitaxel has been formulated into many 
nanoformulations to increase its bioavailability. Our group developed a poly(l-glutamic 
acid)-conjugated paclitaxel (PG-paclitaxel) (Milas et al. 2003; Ke et al. 2001; Li et al. 2000; 
Li et al. 2000). In the OCA-1 ovarian cancer xenograft model, PG-paclitaxel enhanced 
the radiation response by a factor of 7.2–8.4 (Milas et al. 2003). Recently, Werner et al. 
(Werner et al. 2013) compared the radiosensitization of free paclitaxel and PG-paclitaxel 
in non-small cell lung cancer models. PG-paclitaxel had higher sensitizer enhancement 
ratio (SER) in both A549 cells (1.23 vs. 1.12 for paclitaxel) and H460 cells (1.12 vs. 1.03 
for paclitaxel). When combined with 5 daily fractions of 3-Gy radiation, PG-paclitaxel 
led to significantly longer delay of tumor growth than paclitaxel in the H460 xenograft 
model (p  =  0.008). Similarly, Jung et  al. (2012) prepared paclitaxel-loaded polymeric 
nanoparticles to radiosensitize A549 xenograft model. The resultant nanoparticles were 
39.4 nm in size and actively internalized by cancer cells. The volume of tumor treated by 
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nanoparticle and radiation was only 38.9% of un-treated tumor. Currently, PG-paclitaxel 
is under development by CTI Biopharma as paclitaxel poliglumex in combination with 
cetuximab and radiotherapy, to treat patients with head and neck cancer (https://clini-
caltrials.gov). The study is ongoing and its results are pending.
Disruption of DNA damage repair
Ionizing radiation creates DNA damages such as double-strand break, single-strand 
break, and altered bases (Gavande et  al. 2016). The readers are referred to reference 
(Kavanagh et al. 2013) for a broader understanding of radiation-induced DNA damages. 
These DNA damages can be repaired via various pathways including non-homologous 
end joining, homology directed repair, base excision repair etc. Many protein regula-
tors are involved, such as DNA-PK, DNA-ligases, Rad51, and ATM (Lord and Ashworth 
2012). Many chemotherapy drugs can disrupt the DNA damage repair, and subsequently 
enhance radiotherapy (Wieringa et  al. 2016). Several nanoparticle-based formulations 
for inhibition of DNA damage repair are discussed below.
Wang et al. (2015) prepared PLGA-based polymeric nanoparticles to encapsulate his-
tone deacetylase inhibitors (HDACIs). HDACIs disrupt the repair of DNA double-strand 
breaks, and subsequently cause cell death (Chinnaiyan et al. 2005). However, the effect 
of HDACIs is reversible. A prolonged exposure to HDACIs is required to achieve suc-
cessful tumor inhibition and radiosensitization (Lee et al. 2010). Wang et al. utilized the 
nanoformulations to achieve a controlled release of HDACIs in tumor, and therefore to 
extend the drug exposure. In vitro radiosensitization was confirmed via colony survival 
assays and immunostaining of γ-H2AX DSB foci. PC3 (prostate cancer) and SW620 
(colon cancer) xenografts were treated with 3-Gy X-ray irradiation and the nanoparti-
cles. Significantly slower tumor growth was observed in combination groups.
Au et  al. (2015) prepared PEG–PLGA polymeric nanoparticles to encapsulate doc-
etaxel and wortmannin. Docetaxel induces cell cycle arrest in G2/M phases, as well as 
increases ROS production (Rabi and Bishayee 2009). Wortmannin is a potent inhibitor 
for phosphoinositide 3-kinase (PI3-K), and disrupts the repair of DNA damages (Wipf 
and Halter 2005). The resultant nanoparticles were 36 ±  6  nm in size. Up to 40% of 
injected nanoparticles accumulated in tumor, while liver trapped around 60% of injected 
dose. When combined with 8-Gy X-ray radiation, the mean survival of H460 tumor-
bearing mice was 33.2 days longer than non-treatment control, and 28 days longer than 
radiation-only group.
Recently, we have developed several cyclopamine-loaded nanoparticles for radiosen-
sitization (You et al. 2015; Zhao et al. 2015). Cyclopamine is a potent inhibitor for sonic 
hedgehog signaling, and disrupts the repair of radiation-induced DNA damages. When 
testing pancreatic cancer cells, the cyclopamine-loaded polymeric micelles enhanced the 
radiation by a factor ranging from 1.5 to 1.8 along with the extended presence of γ-H2AX 
foci (Zhao et al. 2015). We also evaluated the radiosensitization of cyclopamine-loaded 
lipid nanoparticles in a pancreatic cancer xenograft (Miapaca-2) and a 4T1 breast cancer 
model. 177Lu-conjugated polymeric micelles were used as intratumoral radiation source. 
The combination therapy was more effective in tumor suppression than radiation mono-
therapy in both tumor models.
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Combination with photothermal therapy
It is well known that hollow gold nanostructures exhibited unique optical properties to 
absorb near-infrared light irradiation (Oldenburg et al. 1998), and transform its energy 
into heat (Liu et al. 2008). A myriad of nanoparticles with different chemical composi-
tions and architectures have been developed during the past decades that exhibit pho-
tothermal conversion properties in the near-infrared region of light (Huang et al. 2008; 
Melancon et al. 2011; Song et al. 2015; Xiao et al. 2013).
The nanoparticle-mediated photothermal effects are confined to the close vicinity of 
nanoparticles, and therefore can minimize the damage to adjacent normal tissue. While 
the high-temperature thermal ablation results in acute cell necrosis, hyperthermia (40–
46 °C) can induce cellular biochemical alterations that can synergize with radiation (Roti 
Roti 2008). Diagaradjane et  al. (2008) reported that gold nanospheres induced hyper-
thermia in tumor upon laser irradiation. The tumor perfusion increased, resulting in 
fewer hypoxic regions. As a result, the tumor response to radiotherapy was significantly 
enhanced: the tumor doubling time was 29  days for the combination therapy group, 
compared to 17 days for the radiation monotherapy group. Atkinson et al. (2010) dis-
covered that gold nanosphere-mediated hypothermia depleted the population of breast 
cancer stem cells. While radiation monotherapy enriched the cancer stem cells by 30%, 
the combination therapy with hyperthermia reduced their population by more than 70%. 
Histological analysis also revealed that the combination therapy-treated tumors had 
more differentiated phenotypes. CuS nanoparticles display strong absorption of near-
infrared light, which enabled the photothermal ablation therapy. We recently examined 
[64Cu]–CuS nanoparticles for the dual radiotherapy (by β emission from 64Cu) and pho-
tothermal therapy against 4T1 breast cancer model (Zhou et al. 2015b). Photothermal 
therapy decreased the number of tumor mammospheres, indicating the tumor-initiating 
cells were depleted by photothermal therapy. In  vivo animal study showed that com-
bined photothermal therapy and radiotherapy mediated by [64Cu]–CuS induced better 
anti-tumor activity than either photothermal therapy (mediated by CuS nanoparticles 
plus near-infrared laser) or radiotherapy (mediated by [64Cu]–CuS nanoparticles) alone, 
as judged by significantly reduced number of lung metastasis nodules and prolonged 
survival of mice bearing orthotopic 4T1 breast tumor.
Conclusions and future perspectives
We have reviewed the application of nanoparticles for internal radiotherapy and radio-
sensitization. One of the key premises of nanoparticles is to deposit as much radiation 
energy as possible to tumor and make tumor as vulnerable as possible to radiotherapy. 
Another basic feature of nanoparticles is their multi-functionality and the capability to 
enable multimodality therapy directed to the same treatment volume at the same time. 
It is expected that nanoparticle-based radiotherapy will make significant contributions 
to cancer treatment when successfully translated into the clinic. However, success in 
combining nanomedicine and radiotherapy in the clinic will require advances in multi-
ple fronts. First, the tumor-specific accumulation of nanoparticles is still far from being 
ideal, with a majority of the injected dose in most nano-carriers being sequestered in 
organs of the mononuclear phagocytic system. Future studies are needed to direct more 
efforts toward developing nanoparticle systems with minimal retention in the body 
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after radiotherapy is over. Second, reproducible large-scale production processes must 
be developed and implemented under good manufacturing practice (GMP) guidelines. 
In addition, the biosafety profiles of nanoparticles must be determined using the GMP 
products. These studies are often time-consuming and resource-intensive, and have 
become the bottleneck for clinical translation of any nanoparticle-based therapeutic 
agent. Radiolabeled nanoparticles for internal radiotherapy add another dimension of 
complexity, because radiolabeling often needs to be completed in short time while keep-
ing a satisfactory labeling efficiency and radiostability. The dosimetry of radiolabeled 
nanoparticles also needs to be adequately determined to estimate potential radiation 
exposure to normal organs.
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